S: Sensory organs

ATC group S for modelers: an organ of limited accessibility, with the ophthalmological modeling notes held at S01.
Modified

September 22, 2026

Drugs applied to the eye and the ear. The notes below come from S01, ophthalmologicals, where the difficulty is an organ of limited accessibility, for administering drug and for sampling tissue [1].

In 1977 Thom Zimmerman and Herbert Kaufman studied single-dose timolol at four strengths in twenty patients with chronic open-angle glaucoma. Every strength, down to 0.1%, lowered pressure for at least 24 hours, which led them to propose a once a day topical agent [2].

Table 1: ATC S level 2 codes
Level 2 code Description In plain terms Example drug
S01 Ophthalmologicals medicines applied to the eye Latanoprost (S01EE01) / aflibercept (S01LA05)
S02 Otologicals ear medicines, mostly drops Ciprofloxacin ear drops (S02AA15) / dexamethasone with antiinfectives (S02CA06)
S03 Ophthalmological and otological preparations drops licensed for both eye and ear Residual group for drops licensed for both eye and ear; no separate standard of care. Closest is dexamethasone with antiinfectives (S03CA01); single-agent example ciprofloxacin (S03AA07). Eye and ear disease is treated from S01 and S02 instead.

Modeling notes

Endpoint. In S01E the endpoint is intraocular pressure, read as a 24 hour series rather than one clinic value, because the baseline itself carries a circadian rhythm [3]. Posterior segment endpoints vary: the pegcetacoplan analysis used geographic atrophy lesion area [4], the faricimab analysis best corrected visual acuity [5].

Easy to overlook. For faricimab, vitreous elimination is the slowest step, so vitreous, aqueous and plasma concentrations decline in parallel and the plasma curve reports ocular release rather than systemic clearance [5].

Mechanistic extrapolation. Ocular PBPK is used for tissue too invasive to access in humans: atropine, predicted to penetrate the posterior segment after topical dosing [6], and an ofloxacin ointment, extrapolated from rabbit aqueous humour to human ocular exposure [7]. Ocular QSP exists but is still assembling its data and cellular systems [1].

References

[1]
Kuepfer L, Fuellen G, Stahnke T. Quantitative systems pharmacology of the eye: Tools and data for ocular QSP. CPT: Pharmacometrics & Systems Pharmacology 2023;12:288–99. https://doi.org/10.1002/psp4.12918.
[2]
Zimmerman TJ, Kaufman HE. Timolol, dose response and duration of action. Archives of Ophthalmology 1977;95:605–7. https://doi.org/10.1001/archopht.1977.04450040071009.
[3]
Durairaj C, Shen J, Cherukury M. Mechanism-based translational pharmacokinetic-pharmacodynamic model to predict intraocular pressure lowering effect of drugs in patients with glaucoma or ocular hypertension. Pharmaceutical Research 2014;31:2095–106. https://doi.org/10.1007/s11095-014-1311-9.
[4]
Crass RL, Prem K, Gaudreault F, Lusk E, Ribeiro R, Chapel S, et al. Pharmacokinetic/pharmacodynamic analysis of geographic atrophy lesion area in patients receiving pegcetacoplan treatment or sham. CPT: Pharmacometrics & Systems Pharmacology 2025;14:257–67. https://doi.org/10.1002/psp4.13264.
[5]
Diack C, Gibiansky L, Jaminion F, Gibiansky E, Gaudreault J, Bogman K, et al. Ocular pharmacokinetics of faricimab following intravitreal administration in patients with retinal disease. Translational Vision Science & Technology 2024;13:14. https://doi.org/10.1167/tvst.13.11.14.
[6]
Zheng A, Han T, Bu F, He Q, Shang J, Ho PCL, et al. An ocular exposure prediction for topical atropine in human using physiologically based pharmacokinetic modeling. The AAPS Journal 2025;27:89. https://doi.org/10.1208/s12248-025-01052-7.
[7]
Le Merdy M, Tan M-L, Lukacova V. Clinical ocular exposure extrapolation for an ophthalmic ointment using PBPK modeling and simulation. The AAPS Journal 2025;27:150. https://doi.org/10.1208/s12248-025-01138-2.